The purpose of the Biostatistics Core is to provide professional expertise in statistics for all VanderbiltUniversity Breast Cancer SPORE projects, investigators and participants. Functions provided by thiscore include development of experimental designs, data quality control, statistical analysis andinterpretation of findings, and collaboration on presentation of results. To achieve these functions, thecore director and core biostatisticians are constantly available to investigators, and are in regularcontact with the project and pilot project leaders.The primary objectives of the Biostatistics Core are:1. To provide study design and review all laboratory, animal and clinical studies including feasibilityassessment, power analysis and sample size estimation.2. To collaborate in projects data analysis, interpretation of results, and the writing of final study reportsand manuscripts.3. To work with Clinical Core, Imaging Core and Tissue Core in the development of research projectdatabase, to maintain data quality control and to ensure timely data capture.4. To develop and evaluate statistical methods for experimental design and data analysis.The Biostatistics Core support is required in all Breast Cancer SPORE studies. Core personnel haveworked and will continue to work closely with project leaders for assuring that Core provides state-ofthe-art statistical support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA098131-06
Application #
7515292
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2008-09-11
Project End
2013-05-31
Budget Start
2008-09-11
Budget End
2009-05-31
Support Year
6
Fiscal Year
2008
Total Cost
$117,686
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435
Elion, David L; Cook, Rebecca S (2018) Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. Oncotarget 9:29007-29017
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194
Luo, Na; Nixon, Mellissa J; Gonzalez-Ericsson, Paula I et al. (2018) DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun 9:248
Sudhan, Dhivya R; Schwarz, Luis J; Guerrero-Zotano, Angel et al. (2018) Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clin Cancer Res :
Werfel, Thomas A; Wang, Shan; Jackson, Meredith A et al. (2018) Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Res 78:1845-1858
Zhao, Shilin; Li, Chung-I; Guo, Yan et al. (2018) RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics 19:191
Santos Guasch, Gabriela L; Beeler, J Scott; Marshall, Clayton B et al. (2018) p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. iScience 8:236-249
Jovanovi?, Bojana; Sheng, Quanhu; Seitz, Robert S et al. (2017) Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. BMC Cancer 17:241

Showing the most recent 10 out of 341 publications